Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALVO Alvotech	$8.03 -0.2%	$8.57	$7.35 ▼ $13.70	$2.42B	0.1	404,127 shs	221,247 shs
CGON CG Oncology	$33.34 +0.5%	$27.20	$14.80 ▼ $40.47	$2.54B	0.87	823,360 shs	1.40 million shs
MLYS Mineralys Therapeutics	$37.10 -0.2%	$17.92	$8.24 ▼ $39.20	$2.46B	-0.29	2.58 million shs	1.27 million shs
SVA Sinovac Biotech	$6.47	$6.47	$5.73 ▼ $8.75	$644.67M	0.68	N/A	N/A

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALVO Alvotech	0.00%	-3.60%	-5.31%	-17.56%	-25.37%
CGON CG Oncology	0.00%	+0.82%	+28.43%	+28.92%	-8.66%
MLYS Mineralys Therapeutics	0.00%	+6.61%	+162.56%	+159.08%	+218.73%
SVA Sinovac Biotech	0.00%	0.00%	0.00%	0.00%	0.00%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALVO Alvotech	$8.03 -0.2%	$8.57	$7.35 ▼ $13.70	$2.42B	0.1	404,127 shs	221,247 shs
CGON CG Oncology	$33.34 +0.5%	$27.20	$14.80 ▼ $40.47	$2.54B	0.87	823,360 shs	1.40 million shs
MLYS Mineralys Therapeutics	$37.10 -0.2%	$17.92	$8.24 ▼ $39.20	$2.46B	-0.29	2.58 million shs	1.27 million shs
SVA Sinovac Biotech	$6.47	$6.47	$5.73 ▼ $8.75	$644.67M	0.68	N/A	N/A

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALVO Alvotech	0.00%	-3.60%	-5.31%	-17.56%	-25.37%
CGON CG Oncology	0.00%	+0.82%	+28.43%	+28.92%	-8.66%
MLYS Mineralys Therapeutics	0.00%	+6.61%	+162.56%	+159.08%	+218.73%
SVA Sinovac Biotech	0.00%	0.00%	0.00%	0.00%	0.00%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALVO Alvotech	2.50	Moderate Buy	$14.00	74.35% Upside
CGON CG Oncology	2.92	Moderate Buy	$53.91	61.69% Upside
MLYS Mineralys Therapeutics	2.83	Moderate Buy	$43.50	17.25% Upside
SVA Sinovac Biotech	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest SVA, CGON, MLYS, and ALVO Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/11/2025	MLYS Mineralys Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$26.00 ➝ $50.00
9/9/2025	MLYS Mineralys Therapeutics	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$32.00 ➝ $52.00
9/8/2025	CGON CG Oncology	Jones Trading Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$50.00
9/8/2025	CGON CG Oncology	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight	$75.00
9/8/2025	MLYS Mineralys Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$42.00
9/5/2025	CGON CG Oncology	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$75.00
9/3/2025	MLYS Mineralys Therapeutics	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Hold	$15.00 ➝ $26.00
9/1/2025	CGON CG Oncology	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold
8/28/2025	MLYS Mineralys Therapeutics	Bank of America Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$38.00 ➝ $43.00
8/18/2025	CGON CG Oncology	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Overweight	$55.00
8/18/2025	ALVO Alvotech	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold

(Data available from 9/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALVO Alvotech	$560.10M	4.32	N/A	N/A	($1.37) per share	-5.86
CGON CG Oncology	$551K	4,613.63	N/A	N/A	$9.63 per share	3.46
MLYS Mineralys Therapeutics	N/A	N/A	N/A	N/A	$3.84 per share	N/A
SVA Sinovac Biotech	$448.27M	1.44	$0.17 per share	38.95	$120.83 per share	0.05

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALVO Alvotech	-$231.86M	$0.23	34.91	40.15	N/A	11.26%	-38.36%	9.28%	11/12/2025 (Estimated)
CGON CG Oncology	-$88.04M	-$1.77	N/A	N/A	N/A	-15,945.17%	-19.37%	-18.72%	11/11/2025 (Estimated)
MLYS Mineralys Therapeutics	-$177.81M	-$3.56	N/A	N/A	N/A	N/A	-70.44%	-65.51%	11/10/2025 (Estimated)
SVA Sinovac Biotech	-$99.92M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A

Latest SVA, CGON, MLYS, and ALVO Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2025	Q2 2025	ALVO Alvotech	-$0.26	$0.14	+$0.40	$0.14	$120.51 million	$116.02 million
8/12/2025	Q2 2025	MLYS Mineralys Therapeutics	-$0.78	-$0.66	+$0.12	-$0.66	N/A	N/A
8/8/2025	Q2 2025	CGON CG Oncology	-$0.49	-$0.54	-$0.05	-$0.54	$0.11 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALVO Alvotech	N/A	N/A	N/A	N/A	N/A
CGON CG Oncology	N/A	N/A	N/A	N/A	N/A
MLYS Mineralys Therapeutics	N/A	N/A	N/A	N/A	N/A
SVA Sinovac Biotech	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALVO Alvotech	N/A	1.82	1.27
CGON CG Oncology	N/A	22.15	22.15
MLYS Mineralys Therapeutics	N/A	15.12	15.12
SVA Sinovac Biotech	N/A	N/A	N/A

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALVO Alvotech	N/A
CGON CG Oncology	26.56%
MLYS Mineralys Therapeutics	84.46%
SVA Sinovac Biotech	N/A

Insider Ownership

Company	Insider Ownership
ALVO Alvotech	0.46%
CGON CG Oncology	7.40%
MLYS Mineralys Therapeutics	25.56%
SVA Sinovac Biotech	12.79%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALVO Alvotech	1,032	301.48 million	300.10 million	Not Optionable
CGON CG Oncology	61	76.25 million	70.61 million	Optionable
MLYS Mineralys Therapeutics	28	66.30 million	49.35 million	Optionable
SVA Sinovac Biotech	3,261	99.64 million	86.89 million	Optionable

SVA, CGON, MLYS, and ALVO Headlines

Recent News About These Companies

Sinovac Biotech announces initiative to boost China's biopharmaceutical supply chain

September 1, 2025 | chinadaily.com.cnC

SINOVAC Board Sets the Record Straight on July 8 Special Meeting of ...

July 13, 2025 | morningstar.comM

SINOVAC Board of Directors Provides Update on Status of US$55.00 ...

July 11, 2025 | morningstar.comM

SINOVAC Board Sets the Record Straight on July 8 Special Meeting of Shareholders

July 11, 2025 | businesswire.com

Sinovac Biotech’s New Board Charts Future Path with Strategic Initiatives

July 11, 2025 | tipranks.com

Newly Elected Directors of Sinovac Hold the First Board Meeting

July 10, 2025 | financialpost.comF

Newly Elected Directors of Sinovac Hold the First Board Meeting

July 10, 2025 | businesswire.com

Final Reminder for SINOVAC Shareholders to Vote the WHITE Proxy Card "AGAINST" Misguided Proposals 1 and 2 - Nasdaq

July 9, 2025 | nasdaq.com

SINOVAC Board of Directors Strongly Denounces Deceptive and Illegal Claims by SAIF and the Imposter Former Board

July 9, 2025 | businesswire.com

SINOVAC Board of Directors Provides Update on Status of US$55.00 Special Cash Dividend Payment

July 9, 2025 | businesswire.com

SINOVAC Board of Directors Announces Adjournment of Special Meeting of Shareholders Until Appropriate Court Can Make a Final Decision on the Validity of the PIPE Shares

July 9, 2025 | businesswire.com

Appeal Decision By Eastern Caribbean Supreme Court Supports Right of Prime Success and Vivo Capital to Participate in Critical Sinovac Biotech Shareholder Vote

July 9, 2025 | businesswire.com

Sinovac Biotech Retains Support from Proxy Advisors Ahead of Crucial Vote

July 8, 2025 | tipranks.com

Final Reminder for SINOVAC Shareholders to Vote the WHITE Proxy Card "AGAINST" Misguided Proposals 1 and 2

July 7, 2025 | finance.yahoo.com

Final Reminder for SINOVAC Shareholders to Vote the WHITE Proxy Card “AGAINST” Misguided Proposals 1 and 2

July 7, 2025 | businesswire.com

Federal Court in Massachusetts Denies Vivo Capital’s Petition for Relief on SINOVAC

July 7, 2025 | finance.yahoo.com

Federal Court in Massachusetts Denies Vivo Capital's Petition for Relief on SINOVAC

July 7, 2025 | businesswire.com

Leading Independent Proxy Advisory Firm ISS Joins Glass Lewis in Recommending Shareholders Vote to Keep the Current SINOVAC Board in Place

July 3, 2025 | businesswire.com

United States District Court of Massachusetts Bars Activist 1Globe Capital and Jiaqiang Li From Making Further Materially Misleading Statements Regarding Sinovac

July 2, 2025 | businesswire.com

SAIF Partners: Now is Your Last Chance to Vote for Board Change at Sinovac

July 2, 2025 | businesswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

SVA, CGON, MLYS, and ALVO Company Descriptions

Alvotech NASDAQ:ALVO

$8.03 -0.02 (-0.25%)

Closing price 09/12/2025 04:00 PM Eastern

Extended Trading

$8.02 -0.01 (-0.19%)

As of 09/12/2025 06:15 PM Eastern

Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company's lead program is AVT02, a high concentration formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT04, a biosimilar to Stelara to treat various inflammatory conditions comprising psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT06, a biosimilar to Eylea to treat various conditions, such as age-related macular degeneration, macular edema, and diabetic retinopathy; and AVT03, a biosimilar to Xgeva and Prolia, which is in the pre-clinical phase to treat prevent bone fracture, spinal cord compression, and the need for radiation or bone surgery in patients with certain types of cancer, as well as prevent bone loss and increase bone mass. In addition, it offers AVT05, a biosimilar to Simponi and Simponi Aria, which is in early phase development to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and other indications; AVT16, a biosimilar to an Entyvio product; AVT23, a biosimilar to Xolair, which is in late-stage development to treat nasal polyps; and AVT33, a biosimilar to an Keytruda product. Alvotech was founded in 2013 and is based in Luxembourg, Luxembourg.

CG Oncology NASDAQ:CGON

$33.34 +0.18 (+0.54%)

Closing price 09/12/2025 04:00 PM Eastern

Extended Trading

$33.36 +0.02 (+0.06%)

As of 09/12/2025 04:57 PM Eastern

CG Oncology, Inc., an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients. It also develops PIVOT-006, a cretostimogene monotherapy for intermediate-risk NMIBC following transurethral resection of the bladder tumor; and CORE-008 for treating patients with high-risk NMIBC, including BCG-exposed and BCG-naïve NMIBC patients. CG Oncology, Inc. was formerly known as Cold Genesys, Inc. and changed its name to CG Oncology, Inc. in June 2020. The company was founded in 2010 and is based in Irvine, California.

Mineralys Therapeutics NASDAQ:MLYS

$37.10 -0.06 (-0.16%)

Closing price 09/12/2025 04:00 PM Eastern

Extended Trading

$36.49 -0.61 (-1.64%)

As of 09/12/2025 07:46 PM Eastern

Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone. The company was formerly known as Catalys SC1, Inc. and changed its name to Mineralys Therapeutics, Inc. in May 2020. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.

Sinovac Biotech NASDAQ:SVA

Sinovac Biotech Ltd., a biopharmaceutical company, focuses in the research, development, manufacture, and commercialization of vaccines against human infectious diseases in the People's Republic of China. The company's product portfolio includes vaccines against hepatitis A and B; hand, foot, and mouth diseases caused by enterovirus 71 (EV71); seasonal influenza; H5N1 and H1N1 pandemic influenza; coronavirus; varicella; and mumps. Its marketed products include Healive, an inactivated hepatitis A vaccine; Bilive, a combined inactivated hepatitis A and B vaccine; Anflu, a split viron influenza vaccine; Panflu, a vaccine against the H5N1 influenza virus; Panflu.1, a vaccine against the influenza A H1N1 virus; mumps vaccine to treat viral disease in human species; split viron pandemic influenza vaccine; and Inlive, an EV71 vaccine. The company also offers varicella, a vaccine to treat contagious infectious disease; pneumococcal polysaccharide vaccine, a vaccine to prevent streptococcus pneumoniae infections, such as pneumonia and septicemia; quadrivalent influenza vaccine, a vaccine to protect against two influenza A viruses and two influenza B viruses; and CoronaVac, a vaccine against COVID-19. In addition, its pipeline products include sabin inactivated polio vaccine, a vaccine to treat Poliomyelitis that has completed phase III clinical trial; and rubella vaccine. The company has collaboration agreements with GlaxoSmithKline Biologicals SA to develop combination vaccines containing measles for the China market; Tianjin CanSino Biotechnology Inc. to develop a pneumococcal vaccine; and Instituto Butantan to advance the clinical trials of CoronaVac, an inactivated vaccine candidate against COVID-19 to Phase III. Sinovac Biotech Ltd. was founded in 1993 and is headquartered in Beijing, the People's Republic of China.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest SVA, CGON, MLYS, and ALVO Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest SVA, CGON, MLYS, and ALVO Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

SVA, CGON, MLYS, and ALVO Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

SVA, CGON, MLYS, and ALVO Company Descriptions

Alvotech NASDAQ:ALVO

CG Oncology NASDAQ:CGON

Mineralys Therapeutics NASDAQ:MLYS

Sinovac Biotech NASDAQ:SVA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest SVA, CGON, MLYS, and ALVO Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest SVA, CGON, MLYS, and ALVO Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

SVA, CGON, MLYS, and ALVO Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

SVA, CGON, MLYS, and ALVO Company Descriptions

Alvotech NASDAQ:ALVO

CG Oncology NASDAQ:CGON

Mineralys Therapeutics NASDAQ:MLYS

Sinovac Biotech NASDAQ:SVA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools